Denise Bennett, APRN
Clinical Nurse Specialist · Okarche, OKNPI 1538681747
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 149 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$648
- Shockwave Medical, Inc$566
- AstraZeneca$377
- Kestra Medical Technology Services, Inc.$312
- Abbott$214
- Boehringer Ingelheim$213
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $648 |
| Shockwave Medical, Inc | 28 | $566 |
| AstraZeneca | 15 | $377 |
| Kestra Medical Technology Services, Inc. | 14 | $312 |
| Abbott | 4 | $214 |
| Boehringer Ingelheim | 8 | $213 |
| Novartis | 15 | $184 |
| E.r. Squibb & Sons, L.L.C. | 10 | $181 |
| Amgen | 6 | $145 |
| Actelion Pharmaceuticals US, Inc. | 1 | $137 |
| Johnson & Johnson | 5 | $101 |
| Alnylam Pharmaceuticals Inc. | 3 | $71 |
| Pfizer | 3 | $54 |
| Philips North America LLC | 1 | $47 |
| Abiomed | 1 | $38 |
| Novo Nordisk | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Recor Medical Inc | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$146
- UPTRAVI$137
- OPSUMIT$137
- WAINUA$117
- Repatha$109
How this compares
$3,419 in reported general payments places this provider in the 85th percentile of 56 clinical nurse specialist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $133,798 |
| EntrestoSacubitril/Valsartan | 58 | $45,656 |
| Repatha SureclickEvolocumab | 30 | $30,702 |
| BrilintaTicagrelor | 23 | $17,356 |
| XareltoRivaroxaban | 17 | $16,913 |
| Praluent PenAlirocumab | 17 | $15,476 |
| Atorvastatin Calcium | 328 | $5,511 |
| ClopidogrelClopidogrel Bisulfate | 258 | $5,381 |
| Prasugrel Hcl | 17 | $3,311 |
| Rosuvastatin Calcium | 91 | $1,605 |
| Carvedilol | 114 | $1,468 |
| Metoprolol Succinate | 102 | $1,448 |
| Metoprolol Tartrate | 140 | $1,084 |
| Ezetimibe | 27 | $1,041 |
| Ranolazine ErRanolazine | 11 | $942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $133,798147 claims |
| NovartisEntresto | $184 | $45,65658 claims |
| AstraZenecaBrilinta | $377 | $17,35623 claims |
| Johnson & JohnsonXarelto | $101 | $16,91317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 clinical nurse specialist providers in Oklahoma.
Other clinical nurse specialist in Okarche
- Deborah CrawfordTulsa$11K
- Stacy BootheNorman$7K
- Jessica GriffithTulsa$5K
- Erica MelickOklahoma City$5K
- Kelly Lang-SheppardOklahoma City$5K
- Cheryl WestOklahoma City$4K
- Melissa DimickTulsa$4K
- Lindsey RemmertTulsa$3K
- Stephanie MooreTulsa$3K
- Lauren StegemannTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.